Sarepta Therapeutics Leadership & Management in Cambridge

Key Insight for Candidates

• Strategic Vision & Planning: Leadership has set a focused course to preserve Duchenne revenues while reallocating R&D toward siRNA within defined cost guardrails. Feedback suggests this direction has been consistent across disclosures even amid regulatory turbulence.
• Decisive Leadership: Management demonstrated willingness to make hard calls through a major restructuring that paused lower‑priority programs and reduced spend to preserve long‑term viability. The pivot following safety headwinds indicates readiness to act quickly when conditions change.
• Purposeful Goal Setting: Leaders have framed explicit near‑term guideposts around Elevidys/PMO commercialization, siRNA readouts, and spending constraints. This provides clear waypoints for how progress will be measured through the pivot.

• Lack of Transparency & Communication: Regulatory crises around Elevidys produced mixed signals—initial resistance to an FDA shipment pause followed by a quick reversal and evolving messages—blurring clarity at critical moments. External critiques of disclosure lapses reinforced questions about communication under pressure.
• Poor Execution: Guidance reductions and choppy Elevidys uptake highlighted operational bottlenecks and demand hesitancy, signaling execution gaps during a pivotal year. These disruptions made near‑term plans feel more contingent than intended.
• Siloed or Fragmented Leadership: Commentary around the restructuring period pointed to communication gaps and cross‑functional friction, suggesting uneven coordination across teams. Notes about “chaotic leadership” during a headquarters relocation add to perceptions of inconsistency.